Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E11.59 EPS (ttm)0.32 Insider Own27.99% Shs Outstand47.65M Perf Week2.19%
Market Cap179.94M Forward P/E15.33 EPS next Y0.24 Insider Trans-1.20% Shs Float34.74M Perf Month27.74%
Income15.38M PEG- EPS next Q-0.05 Inst Own55.94% Short Float8.43% Perf Quarter-27.29%
Sales226.63M P/S0.79 EPS this Y-45.93% Inst Trans-2.11% Short Ratio6.22 Perf Half Y-25.55%
Book/sh1.06 P/B3.53 EPS next Y0.00% ROA7.49% Short Interest2.93M Perf Year5.07%
Cash/sh2.22 P/C1.68 EPS next 5Y- ROE40.02% 52W Range2.13 - 7.73 Perf YTD-13.86%
Dividend Est.- P/FCF5.07 EPS past 5Y- ROI13.80% 52W High-51.75% Beta1.08
Dividend TTM- Quick Ratio1.38 Sales past 5Y-0.59% Gross Margin73.44% 52W Low75.12% ATR (14)0.24
Dividend Ex-Date- Current Ratio1.46 EPS Y/Y TTM202.04% Oper. Margin11.74% RSI (14)57.61 Volatility5.64% 7.53%
Employees185 Debt/Eq2.17 Sales Y/Y TTM-3.59% Profit Margin6.78% Recom3.00 Target Price4.33
Option/ShortYes / Yes LT Debt/Eq1.19 EPS Q/Q-436.36% Payout0.00% Rel Volume0.57 Prev Close3.71
Sales Surprise-10.70% EPS Surprise53.85% Sales Q/Q-17.07% EarningsAug 01 AMC Avg Volume470.53K Price3.73
SMA2011.19% SMA502.61% SMA200-13.33% Trades Volume269,462 Change0.54%
Date Action Analyst Rating Change Price Target Change
Sep-28-21Upgrade Citigroup Neutral → Buy $11
Jun-25-20Resumed BofA/Merrill Underperform $9
Oct-08-19Downgrade Goldman Neutral → Sell $24 → $8
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Jul-23-24 09:40AM
Jul-18-24 04:10PM
Jul-02-24 05:30PM
Jun-07-24 05:37PM
Jun-03-24 02:33PM
10:01AM Loading…
Jun-02-24 10:01AM
May-28-24 09:00AM
May-24-24 11:57AM
May-23-24 05:15PM
May-20-24 09:59AM
May-03-24 01:09PM
May-02-24 09:55PM
05:48PM Loading…
Apr-26-24 11:40AM
Apr-25-24 10:02AM
Apr-18-24 04:15PM
Apr-11-24 06:00PM
Apr-03-24 05:30PM
Mar-22-24 09:25AM
Mar-20-24 08:30AM
Mar-02-24 08:29AM
Mar-01-24 09:55AM
Feb-29-24 04:41PM
04:40PM Loading…
Feb-27-24 06:30PM
Feb-22-24 04:10PM
Feb-15-24 04:10PM
Feb-13-24 08:30AM
Jan-31-24 12:58PM
Jan-11-24 04:07PM
Jan-06-24 11:02AM
Dec-11-23 08:30AM
Nov-20-23 11:47AM
Nov-06-23 05:15PM
Nov-03-23 12:16PM
Nov-02-23 07:42PM
Oct-19-23 04:14PM
Oct-14-23 12:30PM
Oct-04-23 05:30PM
Sep-22-23 07:57AM
Sep-21-23 04:10PM
Aug-31-23 04:07PM
Aug-08-23 08:30AM
Aug-04-23 12:36PM
Aug-03-23 05:17PM
Jul-20-23 04:15PM
Jun-13-23 09:30AM
Jun-06-23 05:03PM
Jun-04-23 09:00AM
May-28-23 10:06AM
May-22-23 11:07AM
May-05-23 05:15PM
May-04-23 05:32PM
Apr-20-23 04:15PM
Apr-17-23 06:49AM
Apr-11-23 05:15PM
Mar-14-23 08:30AM
Mar-06-23 09:48AM
Mar-03-23 05:15PM
Mar-02-23 04:05PM
Feb-28-23 04:15PM
Feb-19-23 02:05PM
Feb-16-23 04:31PM
Feb-07-23 05:30PM
Feb-01-23 08:30AM
Jan-25-23 06:19AM
Jan-12-23 04:15PM
Jan-11-23 05:30PM
Jan-09-23 08:55AM
Dec-20-22 08:31AM
Dec-15-22 03:39PM
Dec-07-22 06:03PM
Dec-05-22 05:30PM
Dec-01-22 08:36AM
Nov-28-22 09:55AM
Nov-22-22 09:15AM
Nov-21-22 05:25PM
Nov-17-22 09:40AM
Nov-14-22 10:10AM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AUERBACH ALAN HPresident and CEOJul 17 '24Sale3.7021,92081,1287,063,515Jul 18 06:50 PM
NOUGUES MAXIMO FChief Financial OfficerJul 17 '24Sale3.704,15615,382162,522Jul 18 07:11 PM
HUNT DOUGLAS MSee RemarksJul 17 '24Sale3.703,63713,461133,227Jul 18 06:57 PM
Ludwig Jeffrey JeromeChief Commercial OfficerJul 17 '24Sale3.702,5989,615118,388Jul 18 07:06 PM
AUERBACH ALAN HPresident and CEOJul 02 '24Sale3.2718,88561,7267,085,435Jul 02 09:10 PM
Ludwig Jeffrey JeromeChief Commercial OfficerJul 02 '24Sale3.276,05119,778120,986Jul 02 09:19 PM
NOUGUES MAXIMO FChief Financial OfficerJul 02 '24Sale3.275,29517,307166,678Jul 02 09:22 PM
HUNT DOUGLAS MSee RemarksJul 02 '24Sale3.274,34914,215136,864Jul 02 09:15 PM
WILSON TROY EDWARDDirectorJun 13 '24Sale3.3327,00089,902350Jun 17 07:27 PM
Senderowicz AdrianDirectorJun 13 '24Sale3.3327,00089,8180Jun 17 07:23 PM
MOYES JAY MDirectorJun 13 '24Sale3.3422,00073,46721,322Jun 17 07:21 PM
Dorval AllisonDirectorJun 13 '24Sale3.3711,00037,09633,000Jun 17 07:18 PM
Stuglik Brian MDirectorJun 13 '24Sale3.399,90033,52849,058Jun 17 07:25 PM
AUERBACH ALAN HPresident and CEOJan 03 '24Sale4.4941,396185,6986,936,947Jan 05 06:56 PM
NOUGUES MAXIMO FChief Financial OfficerJan 03 '24Sale4.4915,68270,348128,666Jan 05 06:49 PM
Ludwig Jeffrey JeromeChief Commercial OfficerJan 03 '24Sale4.4912,95658,11999,970Jan 05 07:00 PM
HUNT DOUGLAS MSee RemarksJan 03 '24Sale4.498,35837,493103,319Jan 05 06:42 PM
Wong Alvin FChief Scientific OfficerJan 03 '24Sale4.497,73334,68998,214Jan 05 07:03 PM
Wong Alvin FChief Scientific OfficerDec 04 '23Sale3.762801,05397,934Jan 10 04:41 PM
MILLER MICHAEL PATRICKDirectorNov 07 '23Sale2.8325,00070,80243,358Nov 09 04:19 PM